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Abstract
Background: Blood salvage systems help to minimize intraoperative transfusion of allogenic blood. So far no data
is available on the use of argatroban for anticoagulation of such systems.
We conducted an ex-vivo trial to evaluate the effectiveness of three different argatroban doses as compared to
heparin and to assess potential residual anticoagulant in the red cell concentrates.
Methods: With ethical approval and individual informed consent, blood of 23 patients with contraindications for use
of blood salvage systems during surgery was processed by the Continuous-Auto-Transfusion-System (C.A.T.S. ® Cell
Saver System, Fresenius Kabi, Bad Homburg, Germany) using 5,50 or 250 mg of argatroban or 25.000 U of heparin in
1000 ml saline for anticoagulation of the system. Emergency and high-quality washing modes were applied in random
order. Patency of the system and residual amount of anticoagulants in the re-transfusion bag were measured. The
collected blood was not re-infused, but only used for analysis of hematocrit, heparin and argatroban concentrations.
Results: Patency of the system was provided by all anticoagulants except for 3/8 cases with 5 mg of argatroban.
Residual anticoagulant was found in 2/10 (20 %) heparin samples in two different patients (1 emergency and 1
high-quality washing) and in all argatroban samples. High quality washing eliminated 89–95 % and emergency
washing 60–90 % of the initial argatroban concentration. Residual argatroban concentrations ranged from
55 ng ml−1 to 6810 ng ml−1, with initial argatroban concentrations of 5 and 250 mg, respectively.
Conclusion: The C.A.T.S. does not reliably remove heparin and should therefore not be used in HIT patients.
Anticoagulation with 50 and 250 mg argatroban, maintains the systems patency and is significantly removed
during washing. In this ex-vivo study a concentration of 50 μg ml−1 argatroban provided the best ratio of system
patency and residual argatroban concentration. Additional dose-finding studies with different blood salvage
systems are needed to evaluate the optimal argatroban concentration.
Keywords: HIT, Patient blood management, Alternative anticoagulation, Blood salvage
Background
Transfusion of allogenic blood carries the risk of severe
complications, such as acute transfusion or hemolytic
reactions or transfusion associated lung injury. It may
also increase the risk of bacterial infections [1–3]. Due
to these risks and increasing costs therapeutic alterna-
tives to minimize allogenic transfusions are strongly
recommended. The World Health Organisation re-
cently highlighted the importance of such alternatives,
typically referred to as patient blood management. One
integral part of this “bundle” of measures is the use of
blood salvage systems. These systems collect blood
from the surgical site [4]: the salvaged blood is anticoa-
gulated, washed, filtered and then concentrated for re-
transfusion of “recycled” packed red cells. This method
has been shown to reduce costs and the number of
allogenic transfusions [5–7]. High dose anticoagulation
within the blood salvage system is required to ensure
its patency and to yield an adequate volume of blood
for re-transfusion. Unfractionated heparin (UFH) is
regarded the anticoagulant of choice for this application.
However, there is only scarce evidence for the optimal
anticoagulation regimen of UFH, as well as for the re-
moval of UFH throughout different washing programs.
Therefore, it is not well known, if residual unfractionated
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heparin is still present in the red cell concentrate [8, 9].
As the residual concentrations of unfractionated heparin
can only be measured indirectly, there is some uncertainty
about their potential systemic effects. Even little heparin
amounts may be sufficient to cause complications in
patients with antibodies against platelet factor 4-
heparin-complexes as in patients with heparin-induced
thrombocytopenia (HIT) [10]. HIT is a rare but severe
complication of exposure to heparin with an overall in-
cidence of 1 % in medical patients [11] and up to 10 %
in patients with cardiac assist devices [12]. Although
the incidence of the disease is low, it is frequent enough
to be a clinically relevant problem, because HIT causes
venous and arterial thromboembolic complications due
to an up-regulated pro-coagulatory system [10]. In case
of suspected HIT, all heparin exposure must be stopped
immediately and strictly be avoided, while therapeutic
anticoagulation with an alternative anticoagulant has to
be initiated [13]. Argatroban, a direct thrombin inhibi-
tor, has been approved for this specific indication and
has shown to be safe and effective for anticoagulation
of extracorporeal systems such as continuous renal
replacement therapy and extracorporeal membrane
oxygenation [14, 15].
In contrast, no data are available on the use of arga-
troban for anticoagulation of blood salvage systems.
Patients with a history of HIT or with HIT suspect,
who need to undergo surgery with a major risk of
bleeding, should not be withheld the benefits of patient
blood management, including blood salvage systems.
Nevertheless, exposure to any concentration of heparin
has to be prevented. For this purpose sodium citrate
solutions may be used [16]. Alternatively, blood salvage
systems could be anticoagulated with an alternative
anticoagulant like argatroban in these specific patients.
However, the use of argatroban for anticoagulation of
blood salvage systems has not been studied yet.
Thus, we conducted a prospective randomized ex-vivo
trial to evaluate the effectiveness of the anticoagulant
effect of three different argatroban doses in comparison
to a standard dose of unfractionated heparin and to as-
sess potential residual anticoagulant in the washed red
cell concentrate processed by the blood salvage system
C.A.T.S.®.
Methods
This ex-vivo study was performed in accordance with
the Declaration of Helsinki in its current form after
approval by the Ethics Committee of the Medizinische
Hochschule Hannover (number 897/23.12.2010) and
with patients’ written informed consent to donate their
blood. Patients received oral and written information
about the ex-vivo trial during pre-anesthetic consult-
ation. Patients were eligible for donating their blood if
they were planned to undergo major surgery with an
expected intraoperative blood loss of more than 1 l and
if they had contraindications for the use of a blood
salvage system, such as malignancy or an infection at
the surgical site. Exclusion criteria were age < 18 years,
pregnancy, and surgery with planned use of a cell saver
system. In this trial patients donated their blood to be
treated and studied ex-vivo. Patients were not assigned
to different treatment groups and no patient related
health outcomes were studied. Thus, this research was
not registered in a clinical trials database. The patients
received nor anti-thrombotic treatment nor prophylaxis
before start of operation.
Blood salvage system and randomized anticoagulation
Blood of participants was collected intraoperatively
from the surgical site and randomly assigned by sealed
envelopes to be treated ex-vivo with one out of four
anticoagulation study solutions for the blood salvage
system, each prepared with 1000 ml of saline: 1)
25.000 U of unfractionated heparin (heparin-group), 2)
5 mg argatroban (argatroban 5 mg-group), 3) 50 mg
argatroban (argatroban 50 mg-group) or 4) 250 mg
argatroban (argatroban 250 mg-group). Blood was not
re-transfused after processing.
In all four groups, blood was processed as follows:
The reservoir of the Continuous-Auto-Transfusion-Sys-
tem (C.A.T.S.® Cell Saver System, Fresenius Kabi, Bad
Homburg, Germany) was initially flushed with 100 ml
of the study solution to moisture the internal filter.
Upon start of surgery, a continuous infusion of the
study solution of 100 ml h−1 was started via the routine
surgical suction device in order to immediately anticoa-
gulate the blood collected from the surgical site. To
have comparable conditions in each group, the mixture
of blood and study solution was then harvested into the
reservoir of the blood salvage system until the collected
volume was 600 ml. Then, from the reservoir of each
patient two different washing programs were performed
in random order: 1) emergency washing and 2) high-
quality washing. Each washing program processed
approximately 300 ml of collected blood. The main
difference between the programs is a more intensive
washing procedure using a sevenfold larger washing vol-
ume during high quality wash. In order to avoid interfer-
ence with residual contents of the system after the first
washing program, the connector of the reservoir, the
“washing chamber” and the re-transfusion bag were
exchanged prior to the second washing program.
After washing, the red cell concentrates were pumped
into the re-infusion bag.
In all patients, samples for hematocrit (EDTA monov-
ettes, E 772 G, 3,5 ml, Kabe Labortechnik, Nürnbrecht-
Elsenroth, Germany), heparin and argatroban concentration
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(Sodium citrate monovettes, C 772 G, 4 ml Kabe
Labortechnik, Nürnbrecht-Elsenroth, Germany) were
taken from patients, the reservoir shortly prior to the
start of the first washing program and from each of the
two re-infusion bags after emergency and high quality
washing.
Hematocrit was analyzed in our laboratory immediately
using a Sysmex XN-2000 machine (Sysmex Germany,
Norderstedt, Germany) whereas the citrated probes for
argatroban and heparin concentration measurements were
centrifuged (10 min at 1860 g) and the plasma stored at
−80 °C for subsequent batch analyses.
Since heparin is a polymer consisting of sulfated glucose-
amino-glucans of various chain lengths, the molecular size
and molecular weight ranges widely. Therefore, a defined
molar concentration cannot be measured directly rather
than that plasma level of heparin can only be assessed in-
directly via its pharmacological effect by monitoring the
anti-Xa-activity. This method has a detection threshold
value of < 0, 1 U ml−1 (Gerinnungspraxis Mannheim,
Germany, Prof. Dr. C. E. Dempfle). Direct measurement of
argatroban concentration was performed by high per-
formance liquid chromatography and double mass spec-
trometry detection (Analytical Clinical Concepts GmbH;
Leidersbach) [17].
Sample size and statistics
For the question addressed in this trial, no data or pre-
liminary results were available. Therefore, no formal
sample size estimation had been performed. We pro-
spectively aimed to treat blood from five patients with
each anticoagulation study solution. In case of minor
blood loss or clotting within the blood salvage system,
the study could not be performed. Thus, patients were
consecutively recruited until five cases per study solu-
tion could be completed.
Data are presented as median and range. Hematocrits
were compared between the groups using univariate
ANOVA. Calculations were done with SPSS Statistic
Software Version 21. IBM.
Results
In total 42 patients were eligible for the study and
agreed to donate their blood collected from the surgical
site for the purpose of this trial. In 19 patients blood
loss was minor and thus no blood was processed. In
three patients, blood that had been treated with 5 mg
argatroban in 1000 ml saline clotted in the blood salvage
system and therefore washing could not be performed. As
a result, blood from 20 patients (age 70 (44–83) years, 12
male, 8 female) was processed by the blood salvage sys-
tem, 5 patients per anticoagulatory regimen, each
undergoing emergency and high quality wash. These
patients underwent major surgery due to malignancies.
As no opportunity for irradiation of blood prior to re-
transfusion is available in our hospital, auto-transfusion of
blood from the blood salvage system was contraindicated.
Patients underwent esophagectomy (n = 5), pancreatico-
duodenectomy (n = 7), liver resection (n = 3), gastrectomy
(n = 1), radical hysterectomy (n = 1), rectum amputation
(n = 1), nephrectomy (n = 1) and osteosynthesis for a
pathologic femur fracture (n = 1). Patients preoperative
laboratory measurements did not differ between groups
(Table 1).
Heparin clearance
The study solution of 25.000 U of heparin in 1000 ml sa-
line resulted in a median anti-Xa activity of 1,9 (0,4- 3,8 U
ml−1) in the reservoir bag of the blood salvage system.
This anti-Xa activity resulted in an effective anticoagulant
state preventing the collected blood from clotting. After
using the emergency wash program, heparin content in
the red cell concentrate was below the detection threshold
of 0,1 U ml−1 in four samples and 0,14 U ml−1 in one sam-
ple. After the high quality wash the anti-Xa activity in the
red cell concentrate was below the detection threshold
again in four samples and 0,27 U ml−1 in one sample. The
two red cell concentrates containing residual heparin were
not derived from the same patient. In total, 20 % (2 of 10)
of red cell concentrates contained residual heparin activ-
ity, detectable by the anti-Xa activity test.
Argatroban clearance
Argatroban concentrations in the reservoir were lower
than in the study solution, and increased linearly with
increasing argatroban concentrations in the study solu-
tion (Fig. 1). Of note, washing of the collected blood
could not be performed in three out of 8 cases (38 %)
randomized to 5 mg argatroban in 1000 ml saline because
of clotting within the blood salvage system.
In all other cases blood was successfully processed
without clotting episodes.
As shown in Fig. 2, residual argatroban concentrations
were detected in all red cell concentrates, exhibiting
lower values after high quality washing than after emer-
gency washing. Emergency washing reduced the argatro-
ban concentration to 10–40 % and the high quality wash
reduced it to 5–11 % of the initial value in the reservoir.
For both programs argatroban clearance was higher in
the 50 mg than in the 5 or 250 mg study solution group
(Fig. 2 panel d). However, there relative clearance did
not differ significantly between the three groups.
After high quality washing, the lowest residual concen-
tration was obtained with the 5 mg study solution: 55
(20–105) ng ml−1, while the highest residual concentra-
tions were obtained with the 250 mg study solution: 6810
(3291–9916) ng ml−1.
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Hematocrits
Hematocrits were comparable in all patients prior to
surgery: heparin-group 31 % (28–38 %), argatroban
5 mg-group 33 % (26–38 %), argatroban 50 mg-group
38 % (31–38 %), and argatroban 250 mg-group 30 %
(18–45 %) (p = 0.66). In the reservoir bag, hematocrits
remained comparable in all four groups: heparin-group
38 % (16-48 %), argatroban 5 mg-group 31 % (9–35 %),
argatroban 50 mg-group 36 % (19-42 %), and argatroban
250 mg-group 31 % (24–48 %) (p = 0,58).
Hematocrits in the re-transfusion bags after both
washing modes were approximately two-fold the initial
patient hematocrits and similar after high quality or
emergency washing, respectively:
Heparin-Group 65 % (52–72 %), 68 % (54–75 %),
respectively, argatroban 5 mg-group 67 % (64–72 %),
64 % (51–70 %), argatroban 50 mg-group 68 % (51–74 %),
65 % (60–72 %), argatroban 250 mg-group 65 % (51–
74 %), 68 % (56–77 %) (p = 0,88 for high quality washing
and p = 0,87 for emergency washing).
Discussion
We have studied the use of argatroban in the blood
salvage system C.A.T.S.®. In this ex-vivo-study we tested
the removal of argatroban and a standard heparin dose
by two programs, “emergency wash” and “high quality
wash”. Type and concentration of anticoagulation did
not influence the general performance of the system, as
hematocrits were comparable between groups. Our
results provide additional information on the use of
heparin and new information on the use of argatroban
for anticoagulation within a blood salvage system:
First, although heparin was washed out from the major-
ity of samples, there was residual heparin activity in 20 %.
Thus, the heparin clearance within this system is not per-
fectly reliable. A finding that is consistent with previous re-
ports [9, 18]. The interpretation of our findings has also to
take into account that an absolute measurement of heparin
concentration is not possible [19]. Therefore, we had to
rely on the indirect detection of heparin by its anti-Xa-,
and/or anti-IIa-activity. This indirect method cannot detect
levels of heparin resulting in anti-Xa activities below 0,1 U
ml−1. Therefore, we cannot exclude that heparin levels
below this threshold value might have been present in our
samples and may cause undesirable systemic effects. Con-
sequently, we suggest refraining from using heparin antic-
oagulation for blood salvage systems in patients with
suspected or proven HIT. Patients after HIT, i.e. in cases
where HIT had been diagnosed previously, but where anti-
bodies are no longer detectable at the time of surgery, a
short period of exposure to heparin seems warranted [20].
Second, in patients with proven or suspected HIT
intraoperative auto-transfusion is challenging. So far,
lepirudin and danaparoid have been studied as antico-
agulants for blood salvage systems, but at the moment
both drugs are not broadly available [21, 22]. Regional
citrate anticoagulation might also be employed [16, 23],
but poses the risk of pH-disturbances. To test, whether
argatroban is a suitable alternative we studied its use
during two different washing programs. Emergency
washing is intended to cope with acute and heavy blood
loss. In this situation large volumes are collected in the
reservoir in a short time and have to be processed im-
mediately and fast. In order to achieve this, the volume
of washing solution is 7 times less than for high quality
washing. As a consequence, argatroban clearance was
significantly better with high quality washing.
Table 1 Preoperative coagulation values
Heparin Argatroban Argatroban Argatroban p
25.000 IE 5 mg 50 mg 250 mg
Hemoglobin (mg/dl) 11 [8–12] 11 [8–13] 12 [10–13] 10 [6–16] 0.581
Hematokrit (%) 31 [27–38] 33 [26–38] 37 [30–38] 30 [17–44] 0.540
Quick (%) 103 [63–110] 103 [56–140] 90 [69–99] 85 [73–95] 0.256
aPTT (seconds) 28 [25–44] 31 [28–35] 33 [27–35] 31 [28–33] 0.667
Fibrinogen (mg/dl) 262 [168–347] 272 [115–333] 379 [245–422] 300 [238–327] 0.158
Fig. 1 Argatroban concentration in saline and in the blood salvage
system reservoir. Depicted are the median argatroban concentrations
as measured in the blood salvage system reservoir versus the initial
argatroban concentrations in saline used for anticoagulation of blood
from the surgical field
Beiderlinden et al. BMC Anesthesiology  (2016) 16:37 Page 4 of 7
Due to lack of information on the use of argatroban
with blood salvage systems, we used a very pragmatic
approach and determined three different concentrations
of argatroban for the study solutions. First we selected
50 mg argatroban, because its anticoagulatory potency
correlates to 25.000 U of unfractionated heparin [24].
Then, a tenfold lower and a five times higher concentra-
tion was chosen hoping to approach potential limits of
the lower and upper dosing range. Although we were fi-
nally able to process blood of five patients using the 5 mg
argatroban study solution, the blood of three patients
could not be washed because of clots in the reservoir.
Therefore, a concentration of 5 μg ml−1 in the initial solu-
tion seems to be too low to reliably maintain the patency
of the blood salvage system.
Red blood cell concentrate, yielded after using
50 μg ml−1 argatroban and high quality washing, con-
tained 0,794 μg ml−1 residual argatroban. Thus, re-
transfusion of 1000 ml red blood cell concentrate
would theoretically result in an average argatroban
“bolus dose” of approximately 794 μg. In a patient with
a total blood volume of 6 l, this bolus would result in
an argatroban plasma concentration of 132 ng ml−1. In
comparison the plasma concentrations of argatroban in
a steady state ranges between 300 and 600 ng ml−1.*
Thus, such a single bolus from auto-transfusion would
not be expected to cause clinically relevant anticoagula-
tion. Nevertheless, clinicians would be reluctant to re-
infuse any amount of an anticoagulant into a bleeding
patient. Of note, after emergency washing, the re-
sidual argatroban was three times higher, and would
thus lead to full anticoagulation. The study solution
with 250 μg ml−1 argatroban resulted in an argatro-
ban concentration in the red cell concentrate of
20 μg ml−1 after emergency wash. Depending on the
volume of re-infused blood, this concentration has
the potential to cause an excessive therapeutic antic-
oagulation resulting in a prolonged bleeding situation.
Even with high quality wash the remaining argatroban
concentration of 6,8 μg ml−1 might be harmful, if re-
transfusion of larger volumes of red cell concentrates
is necessary in a bleeding patient. Therefore, the use
a b
c d
Fig. 2 Argatroban concentration in the blood salvage system. Depicted are the median argatroban concentrations in salvaged blood reservoir
(Reservoir) and in the red cell concentrates after emergency and high quality wash. Anticoagulation of the system with argatroban concentration in
saline: a) 5 μg ml−1, b) 50 μg ml−1, or c) 250 μg ml−1; d) Comparison of the relative argatroban clearance after emergency or high quality
wash - argatroban concentration in the reservoir was equalled to 100 %. The relative clearance did not differ significantly differences between
the three groups
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of argatroban concentrations as high as 250 μg ml−1
in the blood salvage system has to be heavily
discouraged.
There is need for a dose finding study with argatroban
concentrations below 50 μg ml−1 for anticoagulation of
the salvaged blood.
This was an “ex-vivo”-study. Although, our design might
come pretty close to the daily business we can only specu-
late about the effect of re-transfusion of red cell concen-
trates with residual argatroban concentrations in a heavily
bleeding patient. Furthermore, for ethical reasons we used
blood collected from patients with malignancies. We did
that as to not withhold auto-transfusions from patients
who would benefit from it. However, coagulation in pa-
tients with malignancies might differ from those without
such a disease. We do not know, whether this might have
influenced our results. We used only one blood salvage
system. Therefore, we cannot rule out, if other systems do
reliably wash out heparin and argatroban.
Conclusion
Using the C.A.T.S.® heparin should not be used for
anticoagulation of this blood salvage system in patients
with suspected or proven HIT, as residual concentrations
may occur. This has been affirmed for argatroban too. A
concentration of 50 μg ml−1 argatroban is more effective
than the 5 μg ml−1 for maintaining system patency, but
seems to result in residual concentrations too high for re-
transfusion. More information about the clinical conse-
quences of auto-transfusion of red cell concentrates with
residual argatroban concentrations and about alternative,
lower doses are needed.
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